The Triple Agonist
LY3437943 — triple GIP/GLP-1/glucagon receptor agonist
Retatrutide is an investigational metabolic peptide being developed for obesity and type 2 diabetes. It is notable as a 'triple agonist' — it engages three different receptors at once, which sets it apart from earlier single- and dual-agonist drugs in clinical research.
No — retatrutide is an investigational drug still in clinical trials and is not FDA-approved. It is not legally available as an approved medicine, and products sold online are unregulated.
Retatrutide is a triple receptor agonist (GIP/GLP-1/glucagon) studied for substantial weight reduction and metabolic improvement in obesity and type 2 diabetes research.
In a Phase 2 NEJM trial, the highest dose was associated with about 24% mean body-weight reduction over 48 weeks. Phase 3 (TRIUMPH) studies are ongoing.
No. Tirzepatide is a dual GIP/GLP-1 agonist; retatrutide adds a third (glucagon) receptor target, which is associated with greater energy expenditure in research. This is educational information based on published research — not medical advice. Always consult a qualified healthcare provider before considering any peptide.
Retatrutide simultaneously activates the GIP, GLP-1, and glucagon receptors. The GLP-1 and GIP components are associated with appetite reduction and improved insulin response, while the glucagon-receptor component is thought to increase energy expenditure — a combination researchers believe drives its large weight-reduction effects.
In a Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023), participants on the highest retatrutide dose lost roughly 24% of body weight over 48 weeks. It is being studied further in the TRIUMPH Phase 3 program. As of mid-2026 it remains investigational and is not approved.
Investigational drug — not FDA-approved. Retatrutide is in clinical trials and is not legally available as an approved medicine. Any product sold as 'retatrutide' outside a clinical trial is unregulated and not verified for identity, purity, or safety.
Last updated: June 2026
See the full Peptide Legal Status TrackerEducational content only — not medical advice. Always consult a qualified healthcare provider before considering any peptide.